| Japanese |
|---|
| Title | 血中Tissue Polypeptide Antigen (TPA) 測定法としてのBEKI TPS IRMAに関する基礎的ならびに臨床的検討 |
|---|
| Subtitle | 技術報告 |
|---|
| Authors | 濱政明宏*, 河中正裕*, 木谷仁昭*, 福地稔* |
|---|
| Authors(kana) | |
|---|
| Organization | *兵庫医科大学核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 31 |
|---|
| Number | 8 |
|---|
| Page | 995-1003 |
|---|
| Year/Month | 1994/8 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」TPA測定法としてのBEKI TPS IRMAキットにつき, 基礎的ならびに臨床的検討を行った. 本法は測定範囲も0U/Lから2,500U/Lまで広範囲の測定が可能であった. 測定手順は1-Step法で, 2時間の反応操作で測定結果が得られた. インキュベーション条件, 回収試験, 再現性等の基礎的検討成績も十分満足できた. ただし, 希釈試験ではTPA同様原点に集束する直線は得られなかった. 本法のカットオフ値は71U/Lで, 偽陽性率は健常人で5.2%, 良性疾患で32.4%と現在活用されているTPA測定法とほぼ同等であった. 悪性疾患での陽性率は原発性肝細胞癌80.8%, 胆管癌60.0%と高率であったが, 悪性疾患全体では34.5%と比較的低率であった. 測定感度以上の測定値が得られた101例でのTPSとTPAの比較では, 両者は相関係数r=0.835, y=0.82x-0.91と良好な相関が得られた. また, 治療効果の評価では本法はきわめて有用であった. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | TPA, IRMA, TPS, Tumor marker. |
|---|
| English |
|---|
| Title | Evaluation of BEKI TPS Radioassay Kit as a One-Step Immunoradiometric Assay Utilizes Monoclonal and Polyclonal Antibodies Specific for Serum Tissue Polypeptide Antigen |
|---|
| Subtitle | |
|---|
| Authors | Akihiro HAMASE, Masahiro KAWANAKA, Hiroaki KITANI, Minoru FUKUCHI |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Nuclear Medicine, Hyogo College of Medicine |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 31 |
|---|
| Number | 8 |
|---|
| Page | 995-1003 |
|---|
| Year/Month | 1994/8 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] We evaluated the usefulness of the BEKI TPS radioassay kit as a one-step immunoradiometric assay (IRMA) utilizes monoclonal and polyclonal antibodies specific for serum tissue polypeptide antigen (TPA). This IRMA was found to be highly sensitive to serum TPA; minimum detectable concentration of TPA was 20 U/L. There were no problems in the intraassay and interassay reproducibility and recovery test. However, dilution test of the patient's serum with higher TPA concentrations showed no linear relationship between TPA concentrations and diluted serum samples. The antigen measured by this IRMA was immunologically similar to TPA, and the TPS concentration was closely correlated (r=0.835, p<0.01) with the TPA concentration in 101 patient's serum. Four out of 77 healthy subjects (5.2%) and 24 out of 74 patients with benign diseases (32.4%) showed a serum concentration over cut-off value of 71 U/L. The serum TPS concentration was elevated in 80 of 232 patients with malignant diseases (34.5%) including 21 of 26 with hepatocellular carcinoma (80.8%) and 9 of 15 with cholangiocarcinoma (60.0%). In addition, the serum TPA level during the clinical couse of patients with malignant diseases was a very useful indicator for the effect of treatment. Thus, our findings suggested that BEKI TPS IRMA kit is a useful assay system for serum TPA as a tumor marker that can be performed by a simple assay operation within about 2 hours. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | TPA, IRMA, TPS, Tumor marker. |
|---|